Published in Cancer Weekly, September 9th, 2003
AlphaMed is collaborating with the University of Missouri in Columbia in this work. The therapy is based on a molecule, labeled with the therapeutic radionuclide lead-212, that is selective to metastatic melanoma cells. Lead-212 decays to bismuth-212, which in turn emits an alpha particle that destroys tumor cells on contact. While melanoma is understood to be relatively radioresistant, alpha particles, with their high-energy deposition, may be effective in metastatic melanoma,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.